Lymphoma in Biological Technology
Navigation Links
Lymphoma in Biological Technology
... N.Y., July 6 /PRNewswire/ -- The Leukemia & lymphoma Society (LLS) and The International Waldenstrom's ...
About The Leukemia & lymphoma Society
The Leukemia & lymphoma Society(R) (LLS) is the world's largest voluntary ...
... ever involving patients with cutaneous T-cell lymphoma on schedule for completion in June 2010 ... for the treatment of early-stage cutaneous T-cell lymphoma (CTCL - stages 1-2a). The study, which is being ... Officer of Yaupon. Cutaneous T-cell lymphoma is a cancer of the T-lymphocytes in the skin. ...
... other investigational uses, there was one case of lymphoma among 2,657 CIMZIA-treated patients and one case of Hodgkin lymphoma among 1,319 placebo-treated patients. In CIMZIA ... and open label) a total of three cases of lymphoma were observed among 2,367 patients. This is ...
... drugs for the treatment of non-Hodgkin's lymphoma (NHL), and a preclinical study evaluating the ... with previously treated CLL or small lymphocytic lymphoma (SLL). Abstract 8571 (May 30, 2009): ... Therapeutic Drugs in Models of Non-Hodgkin's lymphoma In addition, Trubion will also present at the ...
... in patients with relapsed non-Hodgkin's lymphoma and a poster presentation of the first interim ... phase 1 clinical study in relapsed non-Hodgkin's lymphoma patients. These data were published in the ... 2 clinical trial in patients with non-Hodgkin's lymphoma with blinatumomab. In addition, by mid-2009, we ...
... pixantrone for relapsed aggressive non-Hodgkin's lymphoma (NHL) and OPAXIO for non-small cell lung and ... for more information. About Non-Hodgkin's lymphoma Non-Hodgkin's lymphoma (NHL) is caused by the abnormal proliferation of ...
... with follicular NHL. Non-Hodgkin's lymphoma (NHL) is caused by the abnormal proliferation ... for more information. About Non-Hodgkin's lymphoma Non-Hodgkin's lymphoma (NHL) is caused by the abnormal proliferation ...
... majority of high risk or relapsed non-Hodgkin's lymphoma patients." High-dose Zevalin was well tolerated ... low-grade or follicular B-cell non- Hodgkin's lymphoma (NHL), including patients with rituximab ... About Non-Hodgkin's Lymphoma Non-Hodgkin's lymphoma (NHL) is caused by the abnormal proliferation ...
... on the treatment of follicular non-Hodgkin's lymphoma and we would expect it to significantly enhance ... low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL), including patients with rituximab ... with CD20-positive follicular non-Hodgkin's lymphoma who had achieved a partial response or a complete ...
... low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL), including patients with rituximab ... underutilized in the treatment of non-Hodgkin's lymphoma patients, especially among community ... treatment option for patients with follicular lymphoma and I would look forward to the FDA's approving ...
... low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL), including patients with rituximab ... as first-line consolidation therapy in follicular lymphoma patients, was sponsored by Bayer Schering Pharma ... Zevalin in patients with CD20-positive follicular lymphoma who had achieved a partial remission or a ...
... Provid Pharmaceuticals, Inc. and The Leukemia & lymphoma Society (LLS) today jointly announced ... . About The Leukemia & lymphoma Society The Leukemia & lymphoma Society(R), headquartered in White Plains, ...
... in front-line MM and Non-Hodgkin's lymphoma (NHL). Clinical Pipeline Highlights In addition ... for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. ... with multiple myeloma (N=1008) and mantle cell lymphoma (N=155) were integrated and tabulated. In ...
... Drug Designation for the Treatment of Hodgkin's lymphoma in the United States - BOULDER, Colo. and ... trial in relapsed and refractory Hodgkin's lymphoma were presented at the American Society of ... in hematological malignancies. About Hodgkin's lymphoma ...
... pixantrone in patients with relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) for whom anthracycline-related drugs are typically not to be used ... for pixantrone to treat relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). CTI expects to complete the submission this quarter and will ...
... immunotherapeutic with potent in vitro activity against B-cell lymphoma B-cell depletion with agents such as Rituxan(R) has proven successful ... was identified that demonstrated highly potent activities against B-cell lymphoma cells in vitro . The CD79BxDR SCORPION can bind to two different ...
... for Crohn's disease and other investigational uses, there was one case of lymphoma among 2,657 CIMZIA(R)-treated patients and one case of Hodgkin lymphoma among 1,319 placebo-treated patients. The potential role of TNF blocker ...
... to study its compounds initially in rheumatoid arthritis and non-Hodgkin's lymphoma and eventually intends to explore their potential in other inflammatory ... Syk is Sufficient to Disrupt Proliferation and Survival of Non-Hodgkin's lymphoma Cell Lines without Concomitant Inhibition of JAK" (abstract # 1794) ...
... -- At the 10th International Conference on Malignant lymphoma in Lugano, Switzerland data were presented from a phase I/II ... using this combination in patients with follicular or diffuse large B-cell lymphoma are warranted." About the Study Of the 30 patients enrolled on this ...
... with Zevalin over rituximab for relapsed or refractory follicular lymphoma patients following initial therapy and that such results will help grow ... pixantrone phase III clinical trial in aggressive, relapsed non-Hodgkin's lymphoma (NHL), known as the EXTEND or PIX301 trial, are expected in the summer of ...
... ever involving patients with cutaneous T-cell lymphoma on schedule for completion in June 2010 ... for the treatment of early-stage cutaneous T-cell lymphoma (CTCL - stages 1-2a). The study, which is being ... Officer of Yaupon. Cutaneous T-cell lymphoma is a cancer of the T-lymphocytes in the skin. ...
... other investigational uses, there was one case of lymphoma among 2,657 CIMZIA-treated patients and one case of Hodgkin lymphoma among 1,319 placebo-treated patients. In CIMZIA ... and open label) a total of three cases of lymphoma were observed among 2,367 patients. This is ...
Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting
... p.m. ET Track: Developmental Therapeutics, lymphoma and Plasma Cell Disorders Session: New ... 2009 from 2:00 p.m. to 6:00 p.m. ET Track: lymphoma and Plasma Cell Disorders Session: lymphoma and Plasma Cell Disorders Location: Level ...... drugs for the treatment of non-Hodgkin's lymphoma (NHL), and a preclinical study evaluating the ... with previously treated CLL or small lymphocytic lymphoma (SLL). Abstract 8571 (May 30, 2009): ... Therapeutic Drugs in Models of Non-Hodgkin's lymphoma In addition, Trubion will also present at the ...
... in patients with relapsed non-Hodgkin's lymphoma and a poster presentation of the first interim ... phase 1 clinical study in relapsed non-Hodgkin's lymphoma patients. These data were published in the ... 2 clinical trial in patients with non-Hodgkin's lymphoma with blinatumomab. In addition, by mid-2009, we ...
... pixantrone for relapsed aggressive non-Hodgkin's lymphoma (NHL) and OPAXIO for non-small cell lung and ... for more information. About Non-Hodgkin's lymphoma Non-Hodgkin's lymphoma (NHL) is caused by the abnormal proliferation of ...
FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review
... for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy. ... option for follicular B-cell non-Hodgkin's lymphoma patients," said James A. Bianco, M.D., CEO of ... low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL), including patients with rituximab ...... with follicular NHL. Non-Hodgkin's lymphoma (NHL) is caused by the abnormal proliferation ... for more information. About Non-Hodgkin's lymphoma Non-Hodgkin's lymphoma (NHL) is caused by the abnormal proliferation ...
... majority of high risk or relapsed non-Hodgkin's lymphoma patients." High-dose Zevalin was well tolerated ... low-grade or follicular B-cell non- Hodgkin's lymphoma (NHL), including patients with rituximab ... About Non-Hodgkin's Lymphoma Non-Hodgkin's lymphoma (NHL) is caused by the abnormal proliferation ...
... on the treatment of follicular non-Hodgkin's lymphoma and we would expect it to significantly enhance ... low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL), including patients with rituximab ... with CD20-positive follicular non-Hodgkin's lymphoma who had achieved a partial response or a complete ...
... low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL), including patients with rituximab ... underutilized in the treatment of non-Hodgkin's lymphoma patients, especially among community ... treatment option for patients with follicular lymphoma and I would look forward to the FDA's approving ...
... low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL), including patients with rituximab ... as first-line consolidation therapy in follicular lymphoma patients, was sponsored by Bayer Schering Pharma ... Zevalin in patients with CD20-positive follicular lymphoma who had achieved a partial remission or a ...
... Provid Pharmaceuticals, Inc. and The Leukemia & lymphoma Society (LLS) today jointly announced ... . About The Leukemia & lymphoma Society The Leukemia & lymphoma Society(R), headquartered in White Plains, ...
Proteolix's Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
... (WM) is a slow-growing type of non-Hodgkin's lymphoma that starts in white blood cells called B lymphocytes. WM is also called lymphoplasmacytic lymphoma because it occurs when abnormal lymphoplasmacytic ... its safety and efficacy in multiple myeloma, lymphoma and solid tumor malignancies. Proteolix is also ...Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
... complete and partial responses in late stage lymphoma patients. The BiTE antibody could also clear the ... responses in patients with mantle cell lymphoma (MCL) -- a disease that is difficult to treat. ... activity for MT103 in late-stage non-Hodgkin's lymphoma patients and completing preclinical development ...BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
... pivotal trial in patients with cutaneous t-cell lymphoma In October, BioCryst began enrolling patients ... candidate, forodesine HCl for cutaneous t-cell lymphoma (CTCL). As presented at the 2007 American ... trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that the Phase ...Millennium Over-Delivers on 2007 Goals and Financial Guidance
... Company- sponsored Phase III non-Hodgkin's lymphoma (NHL) trial. The trial is evaluating VELCADE ... for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. ... with multiple myeloma (N=1008) and mantle cell lymphoma (N=155) were integrated and tabulated. In ...Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results
... -- Prepare for further expansion in non-Hodgkin's lymphoma through completion of patient enrollment in ... for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. ... with multiple myeloma (N=1008) and mantle cell lymphoma (N=155) were integrated and tabulated. In ...REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
... common. Reports of a type of blood cancer called lymphoma in patients on REMICADE or other TNF blockers are ... a rare type of lymphoma, hepatosplenic T cell lymphoma (HSTL), that often results in death. If you take ... or other TNF blockers, your risk for developing lymphoma or other cancers may increase. You should also ...... in front-line MM and Non-Hodgkin's lymphoma (NHL). Clinical Pipeline Highlights In addition ... for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. ... with multiple myeloma (N=1008) and mantle cell lymphoma (N=155) were integrated and tabulated. In ...
Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
... (RFC-1), in Patients with Relapsed or Refractory lymphoma Reveals Marked Activity in T-Cell Malignancies" ... with relapsed or refractory non- Hodgkin's lymphoma (NHL) and Hodgkin's disease. Responses were ... non-small cell lung cancer and a range of other lymphoma sub-types. The Company's other product candidate ...Genmab Amends HuMax-CD4 Pivotal Study in CTCL
... Receives Orphan Drug Designation for Nodal T-Cell lymphoma Summary: Genmab Announced Today it has Amended ... and for the treatment of refractory nodal T-cell lymphoma in Europe. HuMax-CD4 previously received Fast ... "The potential of HuMax-CD4 in treating T-cell lymphoma patients with unmet medical needs continues to ...... Drug Designation for the Treatment of Hodgkin's lymphoma in the United States - BOULDER, Colo. and ... trial in relapsed and refractory Hodgkin's lymphoma were presented at the American Society of ... in hematological malignancies. About Hodgkin's lymphoma ...
... pixantrone in patients with relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) for whom anthracycline-related drugs are typically not to be used ... for pixantrone to treat relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). CTI expects to complete the submission this quarter and will ...
... immunotherapeutic with potent in vitro activity against B-cell lymphoma B-cell depletion with agents such as Rituxan(R) has proven successful ... was identified that demonstrated highly potent activities against B-cell lymphoma cells in vitro . The CD79BxDR SCORPION can bind to two different ...
BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update
... Phase 2 pivotal study of Forodesine HCl in patients with cutaneous T-cell lymphoma (CTCL), and has enrolled more than half of the targeted patients. The ... successful, that the pivotal trial with Forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization ...... for Crohn's disease and other investigational uses, there was one case of lymphoma among 2,657 CIMZIA(R)-treated patients and one case of Hodgkin lymphoma among 1,319 placebo-treated patients. The potential role of TNF blocker ...
... to study its compounds initially in rheumatoid arthritis and non-Hodgkin's lymphoma and eventually intends to explore their potential in other inflammatory ... Syk is Sufficient to Disrupt Proliferation and Survival of Non-Hodgkin's lymphoma Cell Lines without Concomitant Inhibition of JAK" (abstract # 1794) ...
Cell Therapeutics Net Loss Declines as Operating Expenses Decrease By 58% in Third Quarter 2008
... induction in previously untreated patients with follicular non-Hodgkin's lymphoma based on First-line Indolent Trial data. -- Announced that CTI has ... (BBR2778) for patients with relapsed diffuse large B cell non-Hodgkin's lymphoma (NHL) and anticipates reporting top-line results in November. -- ...Rigel Announces Third Quarter 2008 Financial Results and Clinical Update
... for T-cell lymphoma within the next several months. The ongoing Phase 2 lymphoma clinical trial is continuing and is focused on diffuse large B-cell, ... lymphomas, including chronic lymphocytic leukaemia and small lymphocytic lymphoma (CLL/SLL). Rigel plans to present further results from this ongoing ...BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update
... 6-9, 2008. -- The forodesine HCl pivotal trial in cutaneous T-cell lymphoma (CTCL) continues to enroll subjects with CTCL stages IIB through IVA ... successful, that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization ...Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
... response rate in 28 patients with multiply recurrent non-Hodgkin's lymphoma (NHL) who were treated with motexafin gadolinium (MGd, Xcytrin(R)) ... oral Btk inhibitor, PCI-32765, in patients with recurrent B-cell lymphoma in the fourth quarter of calendar 2008. This study is designed to ...Genzyme Files Applications for Approval of Mozobil in the United States and Europe
... for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma. The company has requested priority review of its ... confirmed the potential of Mozobil to effectively and predictably prepare lymphoma and multiple myeloma patients for an autologous transplant. Both studies ...... -- At the 10th International Conference on Malignant lymphoma in Lugano, Switzerland data were presented from a phase I/II ... using this combination in patients with follicular or diffuse large B-cell lymphoma are warranted." About the Study Of the 30 patients enrolled on this ...
BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
... Recent Corporate Highlights Forodesine HCl cutaneous T-cell lymphoma (CTCL) trial update and chronic lymphocytic leukemia (CLL) trial ... successful, that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that the Phase II trial of BCX-4208 for ...Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
... VELCADE is also indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated ... period in 1163 patients with multiple myeloma (N=1008) and mantle cell lymphoma (N=155) were integrated and tabulated. In these studies, the safety ...Genmab Announces Year End 2007 Financial Results
... lymphoma, 2 RA Phase III studies, Phase II relapsed diffuse large B-cell lymphoma study HuMax-CD38 Phase I/II multiple myeloma study Achieved positive ... HuMax-CD20 Phase II RA data Final HuMax-CD4 Phase II cutaneous T-cell lymphoma (CTCL) data R1507 Phase I sarcoma data Presented pre-clinical data: ...... with Zevalin over rituximab for relapsed or refractory follicular lymphoma patients following initial therapy and that such results will help grow ... pixantrone phase III clinical trial in aggressive, relapsed non-Hodgkin's lymphoma (NHL), known as the EXTEND or PIX301 trial, are expected in the summer of ...
CuraGen Reports Fourth Quarter and Year End 2007 Financial Results
... of cancer: -- Updated Phase II results for the treatment of T-cell lymphoma during the second quarter of 2008; -- Updated Phase II results of ... trial of intravenous belinostat for the treatment of peripheral T-cell lymphoma by the fourth quarter of 2008. CR011-vcMMAE, antibody-drug conjugate for ...Other ContentsmelenameningiomameningesmenopausemenopausemenopausetearstearstearstearsmeniscusmeniscusmenorrhagiaOther Tags
(Date:11/25/2009)...ors recently received funding from the National Sc...cial to understanding the environment. The three g...ssistant professor in the Department of Biological...ate research projects. , His first project, titl...unctions from the Leaf to the Landscape," will exa...
(Date:11/24/2009)... may help gut bacteria bind to the gastrointestina...oducers to identify strains that are likely to be ...interact with cells lining the gut to have a benef...e gut they are more likely to stick around long en...ge from the Institute of Food Research. IFR is an...
(Date:11/24/2009)...rets of the earth,s history locked in its icy dept... information on the environments that have been se...ow, a team of researchers from nine institutions ... million dollars by the National Science Foundatio...ly. These scientists will drill through the West A...
Breaking Biology News(10 mins):Kent State University professors focus research on the environment with grants totaling $890,000 2A sticky solution for identifying effective probiotics 2LSU gets to the bottom of things -- in Antarctica 2GENova Biotherapeutics signs collaboration agreement with Prime BioResearch 57276 1GENova Biotherapeutics signs collaboration agreement with Prime BioResearch 57276 2GENova Biotherapeutics signs collaboration agreement with Prime BioResearch 57276 3FDA Approves Vaccines for 2009 H1N1 Influenza Virus 57274 1FDA Approves Vaccines for 2009 H1N1 Influenza Virus 57274 2FDA Approves Vaccines for 2009 H1N1 Influenza Virus 57274 3Diabetes Medications Dont Lower Inflammation 57271 1Diabetes Medications Dont Lower Inflammation 57271 2Diabetes Medications Dont Lower Inflammation 57271 3(Date:11/30/2009)...reening, awareness may help delay progression and ...DAY, Nov. 30 (HealthDay News) -- Medical care for ... $185.5 billion a year, according to a new study. ...hile patients pay $36.1 billion in out-of-pocket c...atient and $4,036 per male patient. Women also hav...
(Date:11/30/2009)...ibutes rise to more women having babies later in l...ews) -- A growing number of children in the United... researchers say. , The overriding reason, expe...s. , Data from 10 regional registries of birth ...mong U.S. children increased by 31 percent between...
(Date:11/30/2009)....C. Finding and treating a tumor without disturbi...e most effective therapies can be invasive and har...ter have devised a way they might deliver the righ...es, called aptamers, which specifically bind to li...of aptamers in a rodent with liver cancer until th...
(Date:11/30/2009)... ShowMyPC has released an online ser... PC; from anywhere. This is the first hosted servi... Remote Desktop program. Result, blazing fast perf... Santa Clara, CA (PRWEB) November 30...hosted Remote Access Service that uses the familia...
(Date:11/30/2009)... To best serve our patients, their c...ted with the Institute of Women,s Health of North ...vaccination. This service is available to all indi...e visit our website to locate a convenient LOCATI... (Vocus) November 30, 2009 -- Accordi...
Breaking Medicine News(10 mins):Health News:Osteoarthritis Costs U.S. Over $185 Billion a Year 2Health News:U.S. Records Increase in Kids With Down Syndrome 2Health News:U.S. Records Increase in Kids With Down Syndrome 3Health News:First live targeting of tumors with RNA-based technology 2Health News:First live targeting of tumors with RNA-based technology 3Health News:ShowMyPC Provides First Online Service in the World to Access Personal Computers from Anywhere Using Microsoft Remote Desktop 2Health News:2009 H1N1 Influenza Vaccination Being Offered at Various Affiliated Campuses of the Institute of Women's Health of North America in Florida 2Health News:2009 H1N1 Influenza Vaccination Being Offered at Various Affiliated Campuses of the Institute of Women's Health of North America in Florida 3[0] Osteoarthritis Costs U.S. Over $185 Billion a Year[0] U.S. Records Increase in Kids With Down Syndrome [0] First live targeting of tumors with RNA-based technology[0] ShowMyPC Provides First Online Service in the World to Access Personal Computers from Anywhere Using Microsoft Remote Desktop[0] 2009 H1N1 Influenza Vaccination Being Offered at Various Affiliated Campuses of the Institute of Women's Health of North America in Florida
BullaeBunionBurnsBunionsBurkittBursaBursitisCachexiaByssinosisCalcificationCamphorCallusCalculusCanavan
Other Tagseggs 2eggs 3eggs 4eggs 5eggs 6eggs 7eggs 8eggs 9eggs 10features 2features 3features 4features 5features 6features 7features 8features 9features 10friends 2friends 3friends 4friends 5friends 6friends 7friends 8friends 9friends 10behaviors 2behaviors 3behaviors 4behaviors 5behaviors 6behaviors 7behaviors 8behaviors 9behaviors 10couples 2upstream 2progresses 2eradicate 2
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |